137 related articles for article (PubMed ID: 15128006)
1. Chemotherapy for metastatic breast cancer.
Biganzoli L; Minisini A; Aapro M; Di Leo A
Curr Opin Obstet Gynecol; 2004 Feb; 16(1):37-41. PubMed ID: 15128006
[TBL] [Abstract][Full Text] [Related]
2. New developments in chemotherapy of advanced breast cancer.
Lebwohl DE; Canetta R
Ann Oncol; 1999; 10 Suppl 6():139-46. PubMed ID: 10676565
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
Bullock K; Blackwell K
Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
[TBL] [Abstract][Full Text] [Related]
4. Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy.
Crown J; Pegram M
Breast Cancer Res Treat; 2003; 79 Suppl 1():S11-8. PubMed ID: 12868801
[TBL] [Abstract][Full Text] [Related]
5. [Role of taxanes in treatment of breast cancer].
Gorbunova VA; Besova NS
Vopr Onkol; 2004; 50(4):492-500. PubMed ID: 15605777
[No Abstract] [Full Text] [Related]
6. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
7. The role of taxanes in the treatment of breast cancer.
Nabholtz JM; Gligorov J
Expert Opin Pharmacother; 2005 Jun; 6(7):1073-94. PubMed ID: 15957963
[TBL] [Abstract][Full Text] [Related]
8. New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin).
Nabholtz JM; Slamon D
Semin Oncol; 2001 Feb; 28(1 Suppl 3):1-12. PubMed ID: 11301369
[TBL] [Abstract][Full Text] [Related]
9. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab/chemotherapy combinations in metastatic breast cancer.
Ligibel JA; Winer EP
Semin Oncol; 2002 Jun; 29(3 Suppl 11):38-43. PubMed ID: 12138396
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
[TBL] [Abstract][Full Text] [Related]
12. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
Nabholtz JM; Reese DM; Lindsay MA; Riva A
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S75-9. PubMed ID: 12435291
[TBL] [Abstract][Full Text] [Related]
13. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Baselga J
Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
Zhu ZL; Zhang J; Chen ML; Li K
Asian Pac J Cancer Prev; 2013; 14(12):7111-6. PubMed ID: 24460260
[TBL] [Abstract][Full Text] [Related]
15. HER2 overexpressing metastatic breast cancer.
Spigel DR; Burstein HJ
Curr Treat Options Oncol; 2002 Apr; 3(2):163-74. PubMed ID: 12057079
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
Ardavanis A; Kountourakis P; Kyriakou F; Malliou S; Mantzaris I; Garoufali A; Yiotis I; Scorilas A; Baziotis N; Rigatos G
Oncologist; 2008 Apr; 13(4):361-9. PubMed ID: 18448549
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with trastuzumab (herceptin).
Vogel CL; Franco SX
Breast J; 2003; 9(6):452-62. PubMed ID: 14616939
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab: new indication. Metastatic breast cancer, in combination with docetaxel: promising, but more evaluation is needed.
Prescrire Int; 2006 Feb; 15(81):3-5. PubMed ID: 16548094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
